Potential cisapride-erythromycin interaction;Interaction potentielle entre le cisapride et l'erythromycine

Canadian Journal of Clinical Pharmacology

Volumn 4, Issue 2, 1997, Pages 82-84

  Tierney, Michael G ^a   Uhthoff, Tara L ^b   Kravcik, Stephen ^b   Wielgosz, Andreas T ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

Cisapride; Drug interaction; Erythromycin; Torsades de pointes

Indexed keywords

CISAPRIDE; CYTOCHROME P450; ERYTHROMYCIN;

ADULT; ARTICLE; CARDIOTOXICITY; CASE REPORT; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; ORAL DRUG ADMINISTRATION; QT INTERVAL; TORSADE DES POINTES;

EID: 0030823826     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47:116-52.
2. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-8.
3. Rizwanuddin AS, Wolfe SM. Cisapride and torsade des pointes. Lancet 1995;345:508.
4. Brandiss MW, Richardson WS, Barold SS. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de points): case report. Clin Infect Dis 1994;18:995-8.
5. Oberg KC, Bauman JL. QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 1995;15:687-92.
6. Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993;88:1832-44.
7. Haefeli WE, Schoenenberger, Weiss P, Ritz R. Possible risk for cardiac arrhythmia related to intravenous erythromycin. Intens Care Med 1992;18:469-73.
8. Janssen Pharmaceutica Inc. Prepulsid Product Monograph, 1995.
9. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-24.